Common Pitfalls in Biotech Company Financing: Risks of Inadequate Protection of Technology and Trade Secrets_Common Technology Protection Pitfalls in Biotech Company Financing

Time:2025-09-03 Views:1422

Risks of Inadequate Protection of Technological and Trade Secrets Biotech companies often face the risk of inadequate protection of their technology and trade secrets during financing, which can harm their interests and even hinder their long-term development. The following are common technology protection pitfalls encountered by biotech companies during financing. 1. Inadequate confidentiality measures Technology secrets are one of a biotech company's most valuable assets, yet many companies neglect to protect them during the financing process. Lack of adequate confidentiality measures can lead to technology leaks, which can then be acquired and exploited by competitors. Biotech companies should establish comprehensive confidentiality systems, including employee confidentiality training, confidentiality agreements, and controlled access to technical documents. 2. Incomplete intellectual property protection Intellectual property, including patents, trademarks, and copyrights, is a core competitive advantage for biotech companies. Inadequate intellectual property protection during financing can lead to risks of intellectual property infringement. Biotech companies should promptly apply for patents and register trademarks to ensure legal protection for their technologies and products. 3. Unclear contract terms When signing contracts with investors, biotech companies often overlook clauses regarding technology protection. Unclear or flawed technology protection clauses could lead to unlawful use or disclosure of the company's technology by investors in the future. Biotech companies should clearly define their responsibilities and obligations regarding technology protection in their contracts to ensure their rights are not infringed. 4. Failure to conduct a risk assessment Before financing, biotech companies often fail to conduct adequate risk assessments, including those for technological and compliance risks. Failure to promptly identify and address potential technology protection risks can lead to serious losses for the company. Biotech companies should conduct a comprehensive risk assessment and develop appropriate technology protection measures before financing. 5. Lack of awareness of technical protection Most importantly, biotech companies lack sufficient awareness of technology protection. Employees, unaware of the serious consequences of technology leaks, may inadvertently disclose company secrets. Biotech companies should strengthen employee training on technology protection, making them aware of the importance of protecting technology and establishing a comprehensive technology protection mechanism.

Quick consultation with a lawyer

Fast Track

Legal consultation service hours

working day: 09:00am–7:00pm

Telephone / Whatsapp / E-mile

Address

8th Floor, Building E, China Overseas International Center, 333 Jiaozi Avenue, Wuhou District, Chengdu